NeuroCovid - a Study of Intensive Care-requiring Covid-19 Patients

Study Overview
=================
Brief Summary
-----------------
Critically ill patients requiring intensive care suffer to a large extent from cognitive deficits involving higher brain functions that primarily affect memory, learning and the ability to concentrate. While the background to this effect is not fully understood, there are growing evidence to support mechanisms related to neuro inflammation and changes in blood flow with concomitant ischemic brain damage. Patients with covid-19 often suffer from severe inflammatory activity with an increased risk of coagulation abnormalities and brain damage. Covid-19 patients requiring intensive care develope more severe impairment of neurological and cognitive function than critically ill intensive care patients who have not covid-19. This project therefore aims to map the link between inflammation, immunology and coagulation systems as well as biochemical and structural changes in the brain with cognitive effects in patients in intensive care for covid-19.

Official Title
-----------------
NeuroCOVID - A Study of Activation and Inhibition of the Immune and Coagulation Systems, the Presence of Biochemical (Blood / CSF) and Structural Brain Changes and Their Association With Long-term Cognitive Dysfunction in Intensive Care-requiring Covid-19 Patients

Conditions
-----------------
Covid19

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥18 years Need for Intensive care Positive PCR test for SARS-CoV-2 Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The association between changes in blood biomarkers for inflammation and the presence of neuroradiologically verified brain injury and neurocognitive disorder |  | Up to 12 months | 
| The association between changes in blood biomarkers for nerve cell damage and the presence of neuroradiologically verified brain injury and neurocognitive disorder |  | Up to 12 months | 
| The association between changes in blood biomarkers for neurodegeneration and the presence of neuroradiologically verified brain injury and neurocognitive disorder |  | Up to 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The association between changes in coagulation factors and the presence of neuroradiologically verified brain injury and / or neurocognitive disorder |  | Up to 12 months | 
| The association between changes in coagulation ability (ROTEM analysis - rotational thromboelastometry) and the presence of neuroradiologically verified brain injury and / or neurocognitive disorder |  | Up to 12 months | 
| The association between changes in inflammatory biomarkers and the presence of neuroradiologically verified brain injury and / or neurocognitive disorder |  | Up to 12 month | 
| Blood biomarker changes of inflammation impact | Markers of inflammation impact - in relation to cerebrospinal fluid changes . | Up to 3 months | 
| Blood biomarker changes of neurological impact | Markers of neurological impact - in relation to cerebrospinal fluid changes . | Up to 3 months | 
| Neuroradiological changes | Neurological impact in relation to cerebrospinal fluid changes | Up to 3 months | 
| Clinical course - Pulmonary gas exchange | in relation to cerebrospinal fluid changes/blood | Up to 3 months | 
| Clinical course - Lung function recording | in relation to cerebrospinal fluid changes/blood | Up to 3 months | 
| Patient characteristics | Patient ICU care data - in relation to cerebrospinal fluid changes | Up to 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
SARS-CoV-2, intensive care, neurocognitive disorders, cognitive dysfunction, biochemical and structural brain changes